

Helen K Reddel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5599999/publications.pdf>

Version: 2024-02-01

221
papers

14,256
citations

25034

57
h-index

22832

112
g-index

224
all docs

224
docs citations

224
times ranked

10966
citing authors

#	ARTICLE	IF	CITATIONS
1	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 59-99.	5.6	1,591
2	Asthma. Lancet, The, 2018, 391, 783-800.	13.7	1,105
3	A summary of the new GINA strategy: a roadmap to asthma control. European Respiratory Journal, 2015, 46, 622-639.	6.7	636
4	Inhaled Combined Budesonide+Formoterol as Needed in Mild Asthma. New England Journal of Medicine, 2018, 378, 1865-1876.	27.0	453
5	A new perspective on concepts of asthma severity and control. European Respiratory Journal, 2008, 32, 545-554.	6.7	372
6	As-Needed Budesonide+Formoterol versus Maintenance Budesonide in Mild Asthma. New England Journal of Medicine, 2018, 378, 1877-1887.	27.0	368
7	Severe and Difficult-to-Treat Asthma in Adults. New England Journal of Medicine, 2017, 377, 965-976.	27.0	357
8	Controlled Trial of Budesonide+Formoterol as Needed for Mild Asthma. New England Journal of Medicine, 2019, 380, 2020-2030.	27.0	308
9	GINA 2019: a fundamental change in asthma management. European Respiratory Journal, 2019, 53, 1901046.	6.7	277
10	Differences between asthma exacerbations and poor asthma control. Lancet, The, 1999, 353, 364-369.	13.7	245
11	The Effect of Inhaled IFN- γ on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 145-154.	5.6	231
12	Overall asthma control: The relationship between current control and future risk. Journal of Allergy and Clinical Immunology, 2010, 125, 600-608.e6.	2.9	219
13	Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. European Respiratory Journal, 2022, 59, 2102730.	6.7	218
14	Underdiagnosis and Overdiagnosis of Asthma. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1012-1020.	5.6	213
15	Inhaler reminders improve adherence with controller treatment in primary care patients with asthma. Journal of Allergy and Clinical Immunology, 2014, 134, 1260-1268.e3.	2.9	198
16	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 17-35.	5.6	196
17	Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet, The, 2019, 394, 919-928.	13.7	180
18	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	13.7	176

#	ARTICLE	IF	CITATIONS
19	The Global Initiative for Asthma (GINA): 25 years later. <i>European Respiratory Journal</i> , 2019, 54, 1900598.	6.7	174
20	Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 1537-1538.	2.9	169
21	Metered-Dose Inhaler Technique: The Effect of Two Educational Interventions Delivered in Community Pharmacy Over Time. <i>Journal of Asthma</i> , 2010, 47, 251-256.	1.7	164
22	Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. <i>Lancet</i> , 2017, 389, 157-166.	13.7	158
23	Optimal asthma control, starting with high doses of inhaled budesonide. <i>European Respiratory Journal</i> , 2000, 16, 226.	6.7	150
24	Evaluation of a novel educational strategy, including inhaler-based reminder labels, to improve asthma inhaler technique. <i>Patient Education and Counseling</i> , 2008, 72, 26-33.	2.2	142
25	The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?. <i>Lancet Respiratory Medicine</i> , 2015, 3, 719-728.	10.7	142
26	Complementary and alternative medicine use in asthma: Who is using what?. <i>Respirology</i> , 2006, 11, 373-387.	2.3	138
27	Treatable traits can be identified in a severe asthma registry and predict future exacerbations. <i>Respirology</i> , 2019, 24, 37-47.	2.3	136
28	“I have lost in every facet of my life” the hidden burden of severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1700765.	6.7	128
29	Mepolizumab effectiveness and identification of super-responders in severe asthma. <i>European Respiratory Journal</i> , 2020, 55, 1902420.	6.7	124
30	The revised 2014 GINA strategy report. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 1-7.	2.6	116
31	Quality Standards for Real-World Research. Focus on Observational Database Studies of Comparative Effectiveness. <i>Annals of the American Thoracic Society</i> , 2014, 11, S99-S104.	3.2	115
32	Integrating real-life studies in the global therapeutic research framework. <i>Lancet Respiratory Medicine</i> , 2013, 1, e29-e30.	10.7	102
33	Adherence Monitoring and E-Health: How Clinicians and Researchers Can Use Technology to Promote Inhaler Adherence for Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 446-454.	3.8	99
34	Asthma control in Australia: a cross-sectional web-based survey in a nationally representative population. <i>Medical Journal of Australia</i> , 2015, 202, 492-496.	1.7	98
35	Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1457-1464.e4.	2.9	88
36	Feasibility and Effectiveness of an Evidence-Based Asthma Service in Australian Community Pharmacies: A Pragmatic Cluster Randomized Trial. <i>Journal of Asthma</i> , 2013, 50, 302-309.	1.7	87

#	ARTICLE	IF	CITATIONS
37	American Thoracic Society/National Heart, Lung, and Blood Institute Asthmaâ€“Chronic Obstructive Pulmonary Disease Overlap Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 375-381.	5.6	86
38	Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 671-680.	10.7	81
39	Measuring asthma control: a comparison of three classification systems. <i>European Respiratory Journal</i> , 2010, 36, 269-276.	6.7	80
40	Asthma and Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2014, 35, 143-156.	2.1	80
41	Early intervention for chronic obstructive pulmonary disease by practice nurse and GP teams: a cluster randomized trial. <i>Family Practice</i> , 2016, 33, 663-670.	1.9	80
42	Patient preferences for managing asthma: results from a discrete choice experiment. <i>Health Economics (United Kingdom)</i> , 2007, 16, 703-717.	1.7	78
43	Long-Term Maintenance of Pharmacists' Inhaler Technique Demonstration Skills. <i>American Journal of Pharmaceutical Education</i> , 2009, 73, 32.	2.1	76
44	Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2255-2261.	3.8	76
45	Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model. <i>Thorax</i> , 2016, 71, 838-846.	5.6	74
46	Double blind randomised controlled trial of two different breathing techniques in the management of asthma. <i>Thorax</i> , 2006, 61, 651-656.	5.6	73
47	Identifying patientâ€“specific beliefs and behaviours for conversations about adherence in asthma. <i>Internal Medicine Journal</i> , 2012, 42, e136-44.	0.8	72
48	Counseling about turbuhaler technique: needs assessment and effective strategies for community pharmacists. <i>Respiratory Care</i> , 2005, 50, 617-23.	1.6	70
49	Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. <i>Internal Medicine Journal</i> , 2016, 46, 1054-1062.	0.8	68
50	Traditional and patient-centred outcomes with three classes of asthma medication. <i>European Respiratory Journal</i> , 2005, 26, 36-44.	6.7	66
51	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, S1-S18.	3.8	66
52	Checklists for Powder Inhaler Technique: A Review and Recommendations. <i>Respiratory Care</i> , 2014, 59, 1140-1154.	1.6	65
53	Metrics of salbutamol use as predictors of future adverse outcomes in asthma. <i>Clinical and Experimental Allergy</i> , 2013, 43, 1144-1151.	2.9	61
54	The GINA asthma strategy report: whatâ€“s new for primary care?. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 15050.	2.6	61

#	ARTICLE	IF	CITATIONS
55	Predicting future risk of asthma exacerbations using individual conditional probabilities. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1494-1502.e3.	2.9	59
56	Using the Community Pharmacy to Identify Patients at Risk of Poor Asthma Control and Factors which Contribute to this Poor Control. <i>Journal of Asthma</i> , 2011, 48, 914-922.	1.7	59
57	Using discrete choice experiments to investigate subject preferences for preventive asthma medication. <i>Respirology</i> , 2007, 12, 127-136.	2.3	58
58	Down-titration from high-dose combination therapy in asthma: Removal of long-acting β_2 -agonist. <i>Respiratory Medicine</i> , 2010, 104, 1110-1120.	2.9	58
59	Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. <i>Respiratory Research</i> , 2011, 12, 38.	3.6	58
60	Working while unwell: Workplace impairment in people with severe asthma. <i>Clinical and Experimental Allergy</i> , 2018, 48, 650-662.	2.9	57
61	Pharmacological strategies for self-management of asthma exacerbations. <i>European Respiratory Journal</i> , 2006, 28, 182-199.	6.7	56
62	Clinical control of asthma associates with measures of airway inflammation. <i>Thorax</i> , 2013, 68, 19-24.	5.6	56
63	Predictors of Severe Exacerbations, Poor Asthma Control, and β_2 -Agonist Overuse for Patients with Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 751-758.e1.	3.8	56
64	The Reliability and Patient Acceptability of the SmartTrack Device: A New Electronic Monitor and Reminder Device for Metered Dose Inhalers. <i>Journal of Asthma</i> , 2012, 49, 657-662.	1.7	55
65	Combination corticosteroid/ β_2 -agonist inhaler as reliever therapy: A solution for intermittent and mild asthma?. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 39-41.	2.9	55
66	User Error With Diskus and Turbuhaler by Asthma Patients and Pharmacists in Jordan and Australia. <i>Respiratory Care</i> , 2011, 56, 1916-1923.	1.6	54
67	Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. <i>BMJ Open</i> , 2017, 7, e016688.	1.9	52
68	The reduction of rhinitis symptoms by nasal filters during natural exposure to ragweed and grass pollen. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 529-532.	5.7	51
69	Inhaler Technique Training and Health-Care Professionals: Effective Long-Term Solution for a Current Problem. <i>Respiratory Care</i> , 2014, 59, 1716-1725.	1.6	51
70	Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. <i>BMJ</i> , The, 2014, 348, g3009-g3009.	6.0	50
71	Severe asthma: Current management, targeted therapies and future directionsâ€”A roundtable report. <i>Respirology</i> , 2017, 22, 53-60.	2.3	50
72	Barriers and facilitators to patient recruitment to a cluster randomized controlled trial in primary care: lessons for future trials. <i>BMC Medical Research Methodology</i> , 2015, 15, 18.	3.1	49

#	ARTICLE	IF	CITATIONS
73	Exacerbations in Adults with Asthma: A Systematic Review and External Validation of Prediction Models. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1942-1952.e15.	3.8	49
74	Effect of Budesonide on the Perception of Induced Airway Narrowing in Subjects with Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 15-21.	5.6	47
75	Analysis of adherence to peak flow monitoring when recording of data is electronic. <i>BMJ: British Medical Journal</i> , 2002, 324, 146-147.	2.3	47
76	Effect of a single day of increased as-needed budesonide/formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 149-158.	10.7	46
77	Pharmacists' perceptions of their role in asthma management and barriers to the provision of asthma services. <i>International Journal of Pharmacy Practice</i> , 2010, 18, 209-216.	0.6	45
78	Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1180-1186.	2.9	45
79	Asthma management in low and middle income countries: case for change. <i>European Respiratory Journal</i> , 2022, 60, 2103179.	6.7	45
80	Systems Biology and Clinical Practice in Respiratory Medicine. The Twain Shall Meet. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1053-1061.	5.6	44
81	Experiences of community pharmacists involved in the delivery of a specialist asthma service in Australia. <i>BMC Health Services Research</i> , 2012, 12, 164.	2.2	43
82	Treatment of overlapping asthma/chronic obstructive pulmonary disease: Can guidelines contribute in an evidence-free zone?. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 546-552.	2.9	43
83	Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. <i>European Respiratory Journal</i> , 2021, 58, 2003927.	6.7	43
84	Diurnal variability--time to change asthma guidelines?. <i>BMJ: British Medical Journal</i> , 1999, 319, 45-47.	2.3	41
85	Breathlessness, Anxiety, Depression, and Function--The BAD-F Study: A Cross-Sectional and Population Prevalence Study in Adults. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 197-205.e2.	1.2	40
86	Should the diagnosis of COPD be based on a single spirometry test?. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16059.	2.6	39
87	Cost-Related Underuse of Medicines for Asthma--Opportunities for Improving Adherence. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2298-2306.e12.	3.8	36
88	Effect of different asthma treatments on risk of cold-related exacerbations. <i>European Respiratory Journal</i> , 2011, 38, 584-593.	6.7	35
89	Effect of novel inhaler technique reminder labels on the retention of inhaler technique skills in asthma: a single-blind randomized controlled trial. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 9.	2.6	35
90	Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand. <i>Respirology</i> , 2021, 26, 1112-1130.	2.3	35

#	ARTICLE	IF	CITATIONS
91	Pitfalls in processing home electronic spirometric data in asthma. <i>European Respiratory Journal</i> , 1998, 12, 853-858.	6.7	34
92	When can personal best peak flow be determined for asthma action plans?. <i>Thorax</i> , 2004, 59, 922-924.	5.6	34
93	A Practical Guide to Implementing SMART in Asthma Management. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, S31-S38.	3.8	34
94	“I’ve said I wish I was dead, you’d be better off without me”: A systematic review of people's experiences of living with severe asthma. <i>Journal of Asthma</i> , 2019, 56, 311-322.	1.7	33
95	The burden of exacerbations in mild asthma: a systematic review. <i>ERJ Open Research</i> , 2020, 6, 00359-2019.	2.6	33
96	Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial. <i>European Respiratory Journal</i> , 2020, 55, 1902073.	6.7	33
97	Rhinovirus-Induced Exacerbations of Asthma. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2010, 43, 227-233.	2.9	32
98	Short-term variability of airway caliber—a marker of asthma?. <i>Journal of Applied Physiology</i> , 2007, 103, 296-304.	2.5	31
99	Global Initiative for Asthma Strategy 2021. <i>Respirology</i> , 2022, 27, 14-35.	2.3	31
100	Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes. <i>Archivos De Bronconeumologia</i> , 2022, 58, 35-51.	0.8	31
101	The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given “as needed” in mild asthma: study protocols for two randomised controlled trials. <i>Trials</i> , 2017, 18, 12.	1.6	30
102	Patient-perceived acceptability and behaviour change benefits of inhaler reminders and adherence feedback: A qualitative study. <i>Respiratory Medicine</i> , 2017, 129, 39-45.	2.9	30
103	Peak flow monitoring in clinical practice and clinical asthma trials. <i>Current Opinion in Pulmonary Medicine</i> , 2006, 12, 75-81.	2.6	29
104	Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. <i>Clinical and Experimental Allergy</i> , 2016, 46, 1407-1415.	2.9	29
105	Prospective observational study in patients with obstructive lung disease: NOVELTY design. <i>ERJ Open Research</i> , 2019, 5, 00036-2018.	2.6	29
106	Session 4A: Community Pharmacy. <i>International Journal of Pharmacy Practice</i> , 2010, 18, 40-43.	0.6	28
107	Rhinoviruses significantly affect day-to-day respiratory symptoms of children with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 663-669.e12.	2.9	27
108	Prevalence and burden of breathlessness in Australian adults: The National Breathlessness Survey—a cross-sectional web-based population survey. <i>Respirology</i> , 2021, 26, 768-775.	2.3	27

#	ARTICLE	IF	CITATIONS
109	“Exasperations” of asthma: a qualitative study of patient language about worsening asthma. Medical Journal of Australia, 2006, 184, 451-454.	1.7	26
110	World Asthma Day. GINA 2014: a global asthma strategy for a global problem. International Journal of Tuberculosis and Lung Disease, 2014, 18, 505-506.	1.2	25
111	A pragmatic cluster randomized controlled trial of early intervention for chronic obstructive pulmonary disease by practice nurse-general practitioner teams: Study Protocol. Implementation Science, 2012, 7, 83.	6.9	24
112	The contribution of goal specificity to goal achievement in collaborative goal setting for the management of asthma. Research in Social and Administrative Pharmacy, 2013, 9, 918-929.	3.0	24
113	Integrated Adherence Monitoring for Inhaler Medications. JAMA - Journal of the American Medical Association, 2019, 321, 1045.	7.4	23
114	Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3069-3077.e6.	3.8	22
115	Does continuous use of inhaled corticosteroids improve outcomes in mild asthma? A double-blind randomised controlled trial. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2008, 17, 39-45.	2.3	21
116	Associations between inhaler technique and asthma control among asthma patients using pressurised MDIs and DPIs. International Journal of Tuberculosis and Lung Disease, 2016, 20, 689-695.	1.2	21
117	“This illness diminishes me. What it does is like theft”. A qualitative meta-synthesis of people's experiences of living with asthma. Health Expectations, 2018, 21, 23-40.	2.6	21
118	Asthma: Time to confront some inconvenient truths. Respiriology, 2010, 15, 194-201.	2.3	20
119	Eosinophilic Inflammation in Subjects with Mild-to-Moderate Asthma with and without Obesity: Disparity between Sputum and Biopsies. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1281-1284.	5.6	20
120	The need for standardisation of peak flow charts. Thorax, 2005, 60, 164-167.	5.6	19
121	Inappropriate prescribing of inhaled corticosteroids: are they being prescribed for respiratory tract infections? A retrospective cohort study. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2013, 22, 201-208.	2.3	18
122	Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma. European Respiratory Journal, 2016, 47, 981-984.	6.7	18
123	Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire data. Journal of Pragmatic and Observational Research, 2018, Volume 9, 29-42.	1.5	18
124	The impact of severe asthma on patients' autonomy: A qualitative study. Health Expectations, 2019, 22, 528-536.	2.6	18
125	Positioning As-needed Budesonide/Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2. Annals of the American Thoracic Society, 2021, 18, 2007-2017.	3.2	17
126	Goals of asthma treatment: how high should we go?. European Respiratory Journal, 2004, 24, 715-717.	6.7	16

#	ARTICLE	IF	CITATIONS
127	Questionnaire Responses That Predict Airway Response to Hypertonic Saline. <i>Respiration</i> , 2005, 72, 52-60.	2.6	16
128	Cost is a major barrier to the use of inhaled corticosteroids for obstructive lung disease. <i>Medical Journal of Australia</i> , 2009, 191, 319-323.	1.7	16
129	Is higher population-level use of ICS/LABA combination associated with better asthma outcomes? Cross-sectional surveys of nationally representative populations in New Zealand and Australia. <i>Respirology</i> , 2017, 22, 1570-1578.	2.3	16
130	Home-based Forced Oscillation Technique Day-to-Day Variability in Pediatric Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1156-1160.	5.6	16
131	Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000217.	3.0	15
132	Patient preferences for asthma management: a qualitative study. <i>BMJ Open</i> , 2020, 10, e037491.	1.9	15
133	The management of mild asthma. <i>European Respiratory Journal</i> , 2021, 57, 2003051.	6.7	15
134	Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2715-2724.e5.	3.8	15
135	Effect of smoking status on the efficacy of the SMART regimen in high risk asthma. <i>Respirology</i> , 2016, 21, 858-866.	2.3	14
136	Inhaler technique education and asthma control among patients hospitalized for asthma in Jordan. <i>Saudi Pharmaceutical Journal</i> , 2018, 26, 1127-1136.	2.7	14
137	“It is like learning how to live all over again”™ A systematic review of people’s experiences of living with a chronic illness from a self-determination theory perspective. <i>Health Psychology and Behavioral Medicine</i> , 2020, 8, 270-291.	1.8	14
138	Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study. <i>Respiratory Medicine</i> , 2022, 200, 106921.	2.9	14
139	Self-management support and other alternatives to reduce the burden of asthma and chronic obstructive pulmonary disease. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 1396-1406.	1.2	13
140	BRONCHODILATOR ACTION OF PRAZOSIN. <i>Lancet</i> , The, 1981, 317, 225.	13.7	12
141	General practitioner-delivered adherence counseling in asthma: feasibility and usefulness of skills, training and support tools. <i>Journal of Asthma</i> , 2016, 53, 311-320.	1.7	12
142	Defining severe obstructive lung disease in the biologic era: an endotype-based approach. <i>European Respiratory Journal</i> , 2019, 54, 1900108.	6.7	12
143	Does the current stepwise approach to asthma pharmacotherapy encourage over-treatment?. <i>Respirology</i> , 2010, 15, 596-602.	2.3	11
144	Treating According to Asthma Control. <i>Clinics in Chest Medicine</i> , 2012, 33, 505-517.	2.1	11

#	ARTICLE	IF	CITATIONS
145	Barriers and outcomes of an evidence-based approach to diagnosis and management of chronic obstructive pulmonary disease (COPD) in Australia: a qualitative study. <i>Family Practice</i> , 2017, 34, cmw103.	1.9	11
146	Absence of back to school peaks in human rhinovirus detections and respiratory symptoms in a cohort of children with asthma. <i>Journal of Medical Virology</i> , 2016, 88, 578-587.	5.0	11
147	As-Needed Budesonide-Formoterol in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 379, 897-898.	27.0	11
148	What matters most to patients when choosing treatment for mild-to-moderate asthma? Results from a discrete choice experiment. <i>Thorax</i> , 2020, 75, 842-848.	5.6	11
149	The cost of asthma medicines. <i>Australian Prescriber</i> , 2018, 41, 34-36.	1.0	11
150	Performance of a brief asthma control screening tool in community pharmacy: a cross-sectional and prospective longitudinal analysis. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2014, 23, 79-84.	2.3	10
151	Budesonide-formoterol reliever therapy in intermittent versus mild persistent asthma. <i>European Respiratory Journal</i> , 2021, 57, 2003064.	6.7	10
152	Inter-professional education unveiling significant association between asthma knowledge and inhaler technique. <i>Pharmacy Practice</i> , 2016, 14, 713.	1.5	10
153	Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study. <i>BMJ Open</i> , 2022, 12, e048537.	1.9	10
154	Dose-dependent pharmacokinetics with single daily dose slow release theophylline in patients with chronic lung disease.. <i>British Journal of Clinical Pharmacology</i> , 1982, 13, 241-243.	2.4	9
155	Measuring peak flow enhances adherence to monitoring in asthma. <i>Thorax</i> , 2007, 62, 741-742.	5.6	9
156	Authors' response. <i>Thorax</i> , 2013, 68, 295.2-296.	5.6	9
157	Barriers to belonging: the need for relatedness amongst people living with severe asthma. <i>Journal of Asthma</i> , 2021, 58, 1-9.	1.7	9
158	Human mesothelioma cells and asbestos-exposed mesothelial cells are selectively resistant to amosite toxicity: a possible mechanism for tumor promotion by asbestos. <i>Carcinogenesis</i> , 1992, 13, 1359-1363.	2.8	8
159	Impact factor and its role in academic promotion. <i>European Respiratory Journal</i> , 2009, 34, 1499-1500.	6.7	8
160	The reliability and utility of spirometry performed on people with asthma in community pharmacies. <i>Journal of Asthma</i> , 2015, 52, 913-919.	1.7	8
161	GINA fosters World Asthma Day 2020 to prevent asthma deaths. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 318, L998-L1000.	2.9	8
162	Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. <i>Drug Safety</i> , 2021, 44, 467-478.	3.2	8

#	ARTICLE	IF	CITATIONS
163	The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study. <i>Respiratory Medicine</i> , 2022, 200, 106863.	2.9	8
164	Severe Asthma Toolkit: an online resource for multidisciplinary health professionals’ needs assessment, development process and user analytics with survey feedback. <i>BMJ Open</i> , 2020, 10, e032877.	1.9	7
165	Effect of Mouthpiece Washing on Aerosol Performance of CFC-Free Ventolin [®] . <i>Journal of Asthma</i> , 2004, 41, 721-727.	1.7	6
166	Obesity and asthma control in an urban population. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 769-770.	2.9	6
167	Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment. <i>BMC Pulmonary Medicine</i> , 2017, 17, 65.	2.0	6
168	Validation of a diagnosis-agnostic symptom questionnaire for asthma and/or COPD. <i>ERJ Open Research</i> , 2021, 7, 00828-2020.	2.6	6
169	Insights from the AUSTRI study on reliever use before and after asthma exacerbations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1916-1918.e2.	3.8	6
170	Lack of Awareness of Need to Clean CFC-Free Metered-Dose Inhalers. <i>Journal of Asthma</i> , 2004, 41, 367-373.	1.7	5
171	The benefit of experience: patient perception of asthma self-management. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2007, 16, 68-70.	2.3	5
172	Pharmacist interventions in asthma. <i>European Respiratory Journal</i> , 2008, 32, 812-812.	6.7	5
173	Characterizing asthma phenotypes: Predictors and outcomes at the extremes of asthma severity. <i>Respirology</i> , 2009, 14, 778-780.	2.3	5
174	Year in Review 2010: Asthma, COPD, cystic fibrosis and airway biology. <i>Respirology</i> , 2011, 16, 540-552.	2.3	5
175	Single maintenance and reliever therapy (SMART) of asthma. <i>Thorax</i> , 2011, 66, 86-87.	5.6	5
176	Impact of graphic format on perception of change in biological data: implications for health monitoring in conditions such as asthma. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2012, 21, 94-100.	2.3	5
177	Control charts demonstrated limited utility for the monitoring of lung function in asthma. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 53-61.	5.0	5
178	Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 449-455.	3.0	5
179	General practitioners' views on the influence of cost on the prescribing of asthma preventer medicines: a qualitative study. <i>Australian Health Review</i> , 2019, 43, 246.	1.1	5
180	“You’ve got to breathe, you know” asthma patients and carers’ perceptions around purchase and use of asthma preventer medicines. <i>Australian and New Zealand Journal of Public Health</i> , 2019, 43, 207-213.	1.8	5

#	ARTICLE	IF	CITATIONS
181	Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetings. <i>Internal Medicine Journal</i> , 2021, 51, 169-180.	0.8	5
182	Rational prescribing for asthma in adults – written asthma action plans. <i>Australian Prescriber</i> , 2012, 35, 78-81.	1.0	5
183	Indices of bronchial reactivity and sensitivity. <i>Thorax</i> , 2011, 66, 265-266.	5.6	4
184	Difficult-to-treat and severe asthma in general practice: delivery and evaluation of an educational program. <i>BMC Family Practice</i> , 2019, 20, 99.	2.9	4
185	Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis. <i>Pharmacoeconomics</i> , 2019, 37, 227-238.	3.3	4
186	Dynamics of inhaled corticosteroid use are associated with asthma attacks. <i>Scientific Reports</i> , 2021, 11, 14715.	3.3	4
187	Rational prescribing for ongoing management of asthma in adults. <i>Australian Prescriber</i> , 2012, 35, 43-46.	1.0	4
188	Novel Methods of Measuring Adherence Patterns Reveal Adherence Phenotypes with Distinct Asthma Outcomes. <i>Annals of the American Thoracic Society</i> , 2022, 19, 933-942.	3.2	4
189	Year in review 2009: Asthma, COPD and airway biology. <i>Respirology</i> , 2010, 15, 365-376.	2.3	3
190	Inconclusive evidence about the efficacy of diverse strategies for intermittent versus daily inhaled corticosteroids for persistent asthma in adults and children. <i>Evidence-Based Medicine</i> , 2014, 19, e2-e2.	0.6	3
191	Living with severe asthma: the role of perceived competence and goal achievement. <i>Chronic Illness</i> , 2019, 17, 174239531988410.	1.5	3
192	Are the 2019 Global Initiative for Asthma (GINA) strategy recommendations applicable to the Canadian context?. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 3-6.	0.5	3
193	Assessment of Airway Responsiveness as a Guide to Diagnosis, Prognosis, and Therapy in Asthma. <i>Allergy and Asthma Proceedings</i> , 1995, 16, 23-26.	2.2	2
194	Action needed on asthma plans. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2011, 20, 116-117.	2.3	2
195	Response: The most fundamental change in asthma management in 30 years?. <i>European Respiratory Journal</i> , 2019, 54, 1901860.	6.7	2
196	GINA recommendations in adults with symptomatic mild asthma and a smoking history. <i>European Respiratory Journal</i> , 2020, 55, 2000068.	6.7	2
197	Reply: About the recommendation of the GINA strategy report on asthma step 1. <i>European Respiratory Journal</i> , 2021, 57, 2004226.	6.7	2
198	Difficult-to-treat and severe asthma in adults: Towards a new treatment paradigm. <i>Australian Journal of General Practice</i> , 2019, 48, 188-192.	0.8	2

#	ARTICLE	IF	CITATIONS
199	Evaluation of difficult-to-treat and severe asthma in adults. , 2019, , 265-284.		2
200	Updated Australian guidelines for mild asthma: what's changed and why?. Australian Prescriber, 2020, 43, 220-224.	1.0	2
201	Common conditions that mimic asthma. Medical Journal of Australia, 2022, 216, 337-340.	1.7	2
202	The Beliefs And Behaviours Which Predict Objectively Measured Adherence To Inhaled Corticosteroids In Asthma. , 2010, , .		1
203	Emerging Concepts in Evidence-Based Asthma Management. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 082-90.	2.1	1
204	“Everybody's Got Asthma” When Misunderstanding and Public Opinion Become Obstacles to the Care of Patients with Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2622-2623.	3.8	1
205	Sodium cromoglycate in asthma. Thorax, 2001, 56, 896-896.	5.6	1
206	Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. , 2018, , .		1
207	Clustering of adherence variability metrics and clinical outcomes in asthma. , 2018, , .		1
208	Increasing the dose of inhaled corticosteroid when asthma deteriorates “ does it prevent severe exacerbations?. Polish Archives of Internal Medicine, 2010, 120, 64-67.	0.4	1
209	Characteristics by physician-assigned severity of asthma, asthma+COPD and COPD patients in the NOVELTY study. , 2019, , .		1
210	Horizontally Compressed Charts Aid Visual Interpretation Of Biological Data. , 2011, , .		0
211	Assessing The Reliability And Validity Of The Smarttrack: An Electronic Adherence Monitor For Pressurized Metered Dose Inhalers (PMDI). , 2011, , .		0
212	“Effect of different asthma treatments on risk of cold-related exacerbations.”H.K. Reddel, C. Jenkins, S. Quirce, M.R. Sears, E.D. Bateman, P.M. O'Byrne, M. Humbert, R. Buhl, T. Harrison, G.G. Brusselle, A. ThorÅ©n, U. Sjöbring, S. Peterson, O. Å–stlund and G.S. Eriksson.<i>Eur Respir J</i>2011; 38: 584–593.: Figure 4. European Respiratory Journal, 2012, 39, 1280-1280.	6.7	0
213	Trends In The Prevalence Of Asthma In Australia. , 2012, , .		0
214	Effect of smoking status on the efficacy of the SMART regimen in high risk asthma “ Reply. Respiriology, 2016, 21, 968-969.	2.3	0
215	Reply: Complexity Analysis of Respiratory Dynamics. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 248-249.	5.6	0
216	Monitoring Adherence to Inhaled Medications“Reply. JAMA - Journal of the American Medical Association, 2019, 322, 693.	7.4	0

#	ARTICLE	IF	CITATIONS
217	Identifying patients at risk for future exacerbations of asthma: Development of a prediction model. , 2015, , .		0
218	Uncovering the reality of life with severe asthma. , 2016, , .		0
219	Identification of treatable traits in a severe asthma registry: prevalence and exacerbation predictors. , 2018, , .		0
220	Reply to "As-needed budesonide-formoterol for adolescents with mild asthma: importance of lung function". Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4179-4180.	3.8	0
221	Reply to: GINA 2021: Asthma in Pre-School Children and SABA-Only Treatment. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	0